Outcome | Stratum | ncases | Increase of d-ROMs by 1 SDa | Decrease of TTL by 1 SDb |
---|---|---|---|---|
RR (95 % CI)c | RR (95 % CI)c | |||
Stratified by cohort/country | ||||
All-cause mortality | HAPIEE Poland | 525 | 1.29 (1.14–1.46)* | 1.14 (1.01–1.28)* |
HAPIEE Czech Republic | 518 | 1.33 (1.17–1.51)* | 1.05 (0.93–1.19) | |
HAPIEE Lithuania | 390 | 1.47 (1.25–1.71)* | 1.31 (1.10–1.57)* | |
ESTHER (Germany) | 269 | 1.33 (1.18–1.49)* | 1.31 (1.15–1.48)* | |
CVD mortality | HAPIEE Poland | 165 | 1.54 (1.21–1.95)* | 1.22 (0.98–1.53) |
HAPIEE Czech Republic | 189 | 1.56 (1.22–2.00)* | 1.25 (0.99–1.56) | |
HAPIEE Lithuania | 155 | 1.40 (1.06–1.85)* | 1.48 (1.06–2.06)* | |
ESTHER (Germany) | 51 | 1.24 (0.94–1.63) | 1.39 (1.06–1.84)* | |
Cancer mortality | HAPIEE Poland | 235 | 1.17 (0.98–1.41) | 1.06 (0.89–1.26) |
HAPIEE Czech Republic | 235 | 1.36 (1.13–1.63)* | 0.95 (0.79–1.14) | |
HAPIEE Lithuania | 158 | 1.60 (1.25–2.04)* | 1.18 (0.89–1.55) | |
ESTHER (Germany) | 74 | 1.40 (1.13–1.74)* | 1.21 (0.96–1.53) | |
Stratified by age | ||||
All-cause mortality | 45 to <60 yearsd | 423 | 1.23 (1.04–1.45)* | 1.16 (1.01–1.34)* |
60 to <70 years | 933 | 1.39 (1.27–1.53)* | 1.16 (1.05–1.29)* | |
70 to <85 yearse, f | 303 | 1.33 (1.17–1.52)* | 1.35 (1.18–1.55)* | |
CVD mortality | 45 to <60 yearsd | 126 | 1.42 (1.01–2.00)* | 1.24 (0.91–1.69) |
60 to <70 yearsd | 322 | 1.64 (1.35–2.00)* | 1.31 (1.09–1.56)* | |
70 to <85 yearse, f | 90 | 1.28 (0.97–1.69) | 1.65 (1.22–2.24)* | |
Cancer mortality | 45 to <60 yearsd | 177 | 1.21 (0.81–1.81) | 1.20 (0.96–1.50) |
60 to <70 yearsd | 392 | 1.41 (1.21–1.64)* | 1.02 (0.86–1.21) | |
70 to <85 yearse, f | 94 | 1.46 (1.13–1.87)* | 1.17 (0.89–1.52) | |
Stratified by sex | ||||
All-cause mortality | Women | 587 | 1.28 (1.13–1.44)* | 1.25 (1.05–1.50)* |
Men | 1115 | 1.40 (1.29–1.53)* | 1.18 (1.08–1.28)* | |
CVD mortality | Womend | 157 | 1.42 (1.08–1.87)* | 1.28 (0.98–1.69) |
Men | 385 | 1.50 (1.27–1.76)* | 1.33 (1.13–1.56)* | |
Cancer mortality | Women | 257 | 1.31 (1.05–1.65)* | 1.16 (0.96–1.40) |
Men | 445 | 1.39 (1.21–1.59)* | 1.06 (0.93–1.21) | |
Stratified by history of MI | ||||
All-cause mortality | No history of MI | 1286 | 1.33 (1.22–1.41)* | 1.17 (1.04–2.61)* |
History of MIg | 375 | 1.39 (1.17;1.65 )* | 1.19 (0.97–1.63) | |
CVD mortality | No history of MI | 379 | 1.35 (1.14–1.57)* | 1.22 (1.04–1.43)* |
History of MId, g | 165 | 1.45 (1.04–2.02)* | 1.19 (0.88–1.61) | |
Stratified by history of cancer | ||||
All-cause mortality | No history of cancer | 1382 | 1.32 (1.23–1.42)* | 1.16 (1.05–1.29)* |
History of cancerg | 257 | 1.49 (1.24–1.77)* | 1.24 (1.00–1.54)* | |
Cancer mortality | No history of cancer | 533 | 1.29 (1.15–1.45)* | 1.01 (0.89–1.14) |
History of cancerg | 169 | 1.53 (1.19–1.97)* | 1.16 (0.91–1.47) | |
Stratified by inflammatory status | ||||
All-cause mortality | CRP ≤3 mg/L | 933 | 1.19 (1.08–1.31)* | 1.12 (0.97–1.30) |
CRP >3 mg/L | 769 | 1.26 (1.15–1.38)* | 1.16 (1.05–1.28)* | |
CVD mortality | CRP ≤3 mg/Ld | 265 | 1.26 (1.00–1.58)* | 1.10 (0.90–1.35) |
CRP >3 mg/L | 275 | 1.28 (1.07–1.54)* | 1.22 (1.01–1.48)* | |
Cancer mortality | CRP ≤3 mg/L | 394 | 1.22 (1.04–1.43)* | 1.06 (0.90–1.26) |
CRP >3 mg/L | 308 | 1.27 (1.10–1.46)* | 1.07 (0.91–1.26) | |
Stratified by time-point of event during follow-up | ||||
All-cause mortality | ≤ year 2 | 419 | 1.46 (1.29–1.66)* | 1.29 (1.11–1.50)* |
> year 2 to ≤ year 4 | 597 | 1.31 (1.17–1.46)* | 1.18 (1.06–1.33)* | |
> year 4 to ≤ year 6 | 433 | 1.25 (1.09–1.43)* | 1.17 (1.02–1.33)* |